R&G PharmaStudies Co. Ltd. A (301333) — Net Asset Quality Index
R&G PharmaStudies Co. Ltd. A (301333) has a Net Asset Quality Index of 83.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.40 Billion minus total liabilities of CN¥397.56 Million yields net assets of CN¥2.00 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See R&G PharmaStudies Co. Ltd. A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
R&G PharmaStudies Co. Ltd. A Net Asset Quality Index Over Time (2019–2025)
This chart shows how R&G PharmaStudies Co. Ltd. A's Net Asset Quality Index has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the index stands at 83.4%, representing net assets of CN¥2.00 Billion against total assets of CN¥2.40 Billion CNY. Explore 301333 operating cash flow to assess how effectively this company generates cash.
Annual Net Asset Quality Index for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below presents the year-by-year Net Asset Quality Index for R&G PharmaStudies Co. Ltd. A from 2019 to 2025, covering 7 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of R&G PharmaStudies Co. Ltd. A.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 82.3% | CN¥1.98 Billion | CN¥2.40 Billion | CN¥423.89 Million | ▲ +3.7 pp |
| 2024 | 78.6% | CN¥1.84 Billion | CN¥2.34 Billion | CN¥500.09 Million | ▼ -6.0 pp |
| 2023 | 84.6% | CN¥1.75 Billion | CN¥2.07 Billion | CN¥319.17 Million | ▼ 0.0 pp |
| 2022 | 84.6% | CN¥1.59 Billion | CN¥1.88 Billion | CN¥289.35 Million | ▲ +20.0 pp |
| 2021 | 64.6% | CN¥437.81 Million | CN¥677.47 Million | CN¥239.66 Million | ▲ +1.8 pp |
| 2020 | 62.8% | CN¥336.98 Million | CN¥536.36 Million | CN¥199.38 Million | ▲ +6.9 pp |
| 2019 | 55.9% | CN¥249.74 Million | CN¥446.86 Million | CN¥197.12 Million | — |